Johnson & Johnson Partners with Sail Biomedicines and Gains Purchase Option

{
  "signal_id": "4764f887-6fb6-4f51-af79-8af314e8cef9",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-07-30T00:25:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://es-us.finanzas.yahoo.com/noticias/johnson-johnson-asocia-sail-biomedicines-002547672.html",
    "title": "Johnson & Johnson Partners with Sail Biomedicines and Gains Purchase Option - Yahoo Finance",
    "excerpt": "Investing.com- Johnson & Johnson (NYSE:JNJ) announced on Wednesday that it has entered into a strategic collaboration with privately held Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, while securing an exclusive option to acquire the biotech company for $2.58 billion. Under the agreements, J&J will collaborate with Sail to advance its lead immune-mediated disease program and its broader in vivo CAR-T platform, designed to reprogram a patient's immune cells directly within the body, rather than relying on traditional cell therapy approaches. As part of the deal, J&J will make total upfront payments of $785 million, which include a $465 million equity investment in Sail, plus up to $140 million in contingent payments tied to development milestones. If the healthcare giant exercises its acquisition option, it would pay an additional $2.58 billion to acquire Sail. J&J noted that the alliance expands its capabilities in in vivo CAR-T therapies, complementing its existing expertise in oncology cell therapies and strengthening its immunology portfolio. The company indicated that it expects the agreements, if the acquisition option is exercised, to reduce adjusted operating earnings per share and adjusted earnings per share by approximately $0.18 in 2026 and by approximately $1.28 in 2027. The transactions are subject to regulatory approvals and...",
    "summary": "Johnson & Johnson has secured an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.",
    "planning": true,
    "image_url": "https://s.yimg.com/cv/apiv2/cv/apiv2/social/images/yahoo-finance-default-logo.png",
    "confidence": 0.9,
    "published_at": "2026-07-30T00:25:00Z",
    "article_sentence": "If the healthcare giant exercises its acquisition option, it would pay an additional $2.58 billion to acquire Sail.",
    "amount_normalized": 2580000000,
    "related_company_name": "Sail Biomedicines",
    "related_company_domain": "sail.bio"
  }
}

curl https://signals.autobound.ai/v1/signals/4764f887-6fb6-4f51-af79-8af314e8cef9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'